Kurve Therapeutics | Marc Giroux, CEO

(Transcription)

Marc Giroux  0:00  

Good morning, and thanks for being here. Kurve Therapeutics is totally focused on neurodegenerative diseases. With the one exception of us doing oncology and treating brain tumors, were doing a new mechanism of action by bypassing the blood brain barrier. So there's a couple of ways of doing this one is to cross overusing and diffusion one is to buy Platt bypass it using the nasal cavity. This is our reason for being a we have, I want you to everybody to know, we have a lot of data. It's impossible in nine minutes to present all of that, but we did bring a really strong science team. Glenn Cornetto chief science officer, and our chief neurologist, Bill shackle is here. And we're happy to do a breakout, to go through all of the data. Okay, so what we're trying to do is a new method of action. And what we're what we're doing is really disruptive. And we're going to be in a new paradigm. The medical industry doesn't do new paradigms terribly well. But we've been doing this for a long time, which is why we have so many so much data. We have 17 peer reviews on just our nose to brain work alone. And we have several others in process. And these are with Harvard Medical School, Johns Hopkins, Karolinska Institute, in Sweden, among many others. So we have some really credible data that we would really like to share in more detail. So please, come see us. First question that everybody's going to ask is, can you bypass the blood brain barrier actually getting the brain? And the answer is yes, you can. The one in the bottom left is somebody looking to the left, and you can see that there's a large bolus right in the olfactory region at the top of the nasal cavity. And then it translates through the cribriform plate and into through the factory neurons. And getting into the brain. The one on the right is the person looking directly at you. And you can see where we take that bolus, and we can concentrate it there. So one of the things we were told, you'll never be able to do is to target in the nasal cavity because it's anatomically impossible to do. And we could, it can, it's a physics issue, not a chemistry issue, not a biology issue. So we solved the physics problems in drug delivery to get it to the area where it's going to do the most good. And we can get it into the brain. Once we did that, this is the we have a lot of data. We took these slides out so we have the wrong presentation. But we're going to run with it. This is the as published in the plenary meeting with Alzheimer's Association a couple of years ago, we were really separating from placebo in our Alzheimer's patients and that's our first target. So in the CNS, we're going to do Alzheimer's, Parkinson's, multiple sclerosis, we've got 15 clinical trials running around the world right now in nose to brain in the plenary meeting as presented at the time. We did we they we separated from placebo and short term memory, attention span verbal fluency. But you can see we also slowed the progression significantly. In the bottom line there, you'll see the our intranasal insulin group significantly slowed. We're also working with a pioneering neurologist who's also here today, his name is Bill Shankle. And we're delivering a polyclonal antibody called IgG. And we're doing that in no spray. Now, the theory behind doing it inter nasally was that you can get 30 times more in the brain if you do it instantaneously than you can with it with an infusion. So we went with a 30 times lower dose, so we're 3,000% lower than an infusion. If you just cast your mind back to a recent Alzheimer's drug approval, they went with their most toxic dose because it was the only one that they had, that was actually showing any benefit. Well, we can do that with 3000 percent less drug going in. So think about the dose flexibility you have in being able to lower the dose and then you can raise it you're not at your ceiling, day one. So Bill Shankle is here. We have a lot of data. Come see us after the after the presentation. These are all the things that we delivered those two brains so far. The stem cells are what we're delivering for glioblastoma. With the exception of live vaccines that are vaccines, we've done all of these things polyclonal monoclonal we've done combination products, nose to brain Well, we did three drugs at a single time. We can also do them in parallel or in series. So the technology platform that we use to do this is very broad, and there's really no liquid that we haven't been able to deliver. Theoretically, we could do a dry powder. What we're planning on being at the leadership of this through the foreseeable future, and what we're looking at right now is we first were the first ones to get drugs empirically into the brain. And that print that is presented here by the yellow section, that's where the drugs are delivered. But what do you do if the brain tumors in the back of the brain, okay, so our storm cloud is the red. And what we're going to do, and what we're we're putting into place right now is taking that yellow drug, and we're going to be able to move it and drop it right on top of that tumor, it doesn't matter where in the brain, your problem is, we're going to be able to put it there, we're going to be able to move it, we can also move it more than once. So the technology platform is going to be able to put some here and then later on, put some there with a single dose. So it's going to be extremely robust. And we're going to be able to now target in the brain like we do in the nasal cavity, we decide where it goes. Our commercialization strategy is razor razor blade, the patient's going to buy that bottom base unit once. And then as they're on it for like Alzheimer's and Parkinson's, we have some of these patients that have been on this technology for 10 years now. They're Alzheimer's patients who still drive cars. So the the, this is a daily use twice a day, every month, that cartridge at the top will empty, you're going to pull it off, throw it away, put a new one on. So we're gonna effectively own that patient. We are a drug company, as well as a device technology platform. But we also have pharmaceutical partners. And this is very attractive because of the ownership of the patient. Either they're using our technology, or they're not getting they're not getting a benefit. We have a whole family of products that we are going to be demonstrating after this presentation. A lot of them are larger and smaller. Depending on the particular application for Parkinson's, we're doing a drug that is going to be delivered at 150 ml per month. That is just a huge amount of liquid so the device got bigger with a bigger reservoir. And we have also some really tiny ones that are smaller than a Flo neighs model that someone will carry around and use every day. Every one of our devices has built in electronics and patient lockouts, counterfeit lockouts, but more importantly, we can do compliance monitoring. We can do dose counting, we can alert the patient that the dose is needed. It's time now for you to take your dose. Right I'm here as the CEO and founder of the company, I can talk to everybody about the technology that we're developing. Tom McDonald is a team member we brought who you want to talk finance. We're going to all be together. Herman plank, here's a VP of manufacturing, you invest in the team. We know that if you want to talk blockchain, Herman is your guy. And for our data. Glenn cornet is our chief science officer. And Bill Shankle will be here. Love to see you guys come out and see us. So we have finished phase one, two and two B. We have good data. And we're planning the end of phase two and we are phase three ready? So we are going to have that meeting with the FDA. We've already had a preliminary meeting on number of patients number of facilities. So we're one study one study from commercial illogic. So we're going to conduct that into phase two meeting. And we're going to have the phase three Alzheimer's program, we're here to announce that we're doing a reggae plus general solicitation, we're gonna raise between 20 and 75 million to fund these things. And the polyclonal antibody Phase Two for Alzheimer's is also on the ticket for the money that we raise. And we're going to out license all of these opportunities, or a lot of these opportunities to follow up because there's simply too much to do for a single company. So, in summary, we've got really favorable clinical trials. And we have very flexible design and active electronics. My time has just clicked off. So please, any questions we'd love to see you.